As of February 2025, the European Union’s classification of titanium dioxide (TiO₂) as a potential carcinogen is under renewed judicial scrutiny. In November 2022, the EU General Court annulled the European Commission’s decision to label certain powder forms of TiO₂ as a Category 2 carcinogen by inhalation. However, on February 6, 2025, Advocate General Ćapeta issued a non-binding opinion recommending that the European Court of Justice (ECJ) overturn this annulment and reinstate the original classification.
Advocate General Ćapeta’s Perspective
Advocate General Ćapeta argues that the General Court exceeded its judicial mandate by substituting its own scientific assessment for that of the European Chemicals Agency’s (ECHA) Risk Assessment Committee (RAC). She emphasizes that the General Court should have limited its review to procedural aspects, ensuring that the Commission considered all relevant scientific data, rather than re-evaluating the scientific conclusions itself. This stance suggests that the General Court encroached upon the administrative jurisdiction of the Commission, which is responsible for scientific evaluations in regulatory matters.
Industry Concerns
The industry has strongly criticised Advocate General Ćapeta’s opinion, expressing concerns that overturning the annulment would grant the European Commission “carte blanche” in making scientific judgments without adequate oversight. Critics argue that enforcing a classification lacking sufficient scientific consensus could lead to unnecessary regulatory burdens and economic implications for industries utilising TiO₂. They contend that the initial classification was based on studies indicating potential carcinogenicity through inhalation of certain powder forms of TiO₂, but these studies do not conclusively demonstrate a significant risk under typical industrial or consumer exposures.
Implications for Industries
If the ECJ decides to reinstate the carcinogenic classification of TiO₂, several industries could face significant challenges:
-
Regulatory Compliance: Manufacturers may need to update labelling and safety data sheets to align with the new classification, ensuring that all products meet the revised regulatory standards.
-
Market Dynamics: Products containing TiO₂ might experience reduced consumer demand due to heightened health concerns, potentially leading to reformulation efforts or the search for alternative substances.
-
Legal Precedents: Reinstating the classification could set a precedent for how scientific data is interpreted in regulatory decisions, influencing future classifications of other substances.
Concerns About EU Overreach
Critics argue that if the European Commission’s classification is reinstated without addressing the scientific ambiguities highlighted by the General Court, it could be perceived as the EU overstepping its authority. This concern centers on the balance between precautionary regulatory actions and decisions grounded in comprehensive scientific evidence.
The ongoing debate over TiO₂’s classification underscores the complexities at the intersection of science, regulation, and industry interests. As the ECJ deliberates on this matter, stakeholders across various sectors are closely monitoring the potential ramifications for regulatory practices and the broader implications for industry operations within the EU.
COURT OF JUSTICE OF THE EUROPEAN UNION
